Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous ...
In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...
Recursion Pharmaceuticals, Inc. (RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 studies. It ...
Recursion Pharmaceuticals (NASDAQ:RXRX) presented its fourth quarter and full-year 2025 results on February 25, 2026, showcasing the first clinical validation of its AI-driven drug discovery platform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results